- Zoetis experts will present two scientific abstracts at the 2025 ACVIM Forum.
- The leading insights focus on AI-powered analysis of canine and feline urine sediment samples and its clinical importance for veterinary teams.
PARSIPPANY, N.J. – June 10, 2025 – Zoetis Inc., the world’s leading animal health company, will present its latest scientific research on Vetscan Imagyst® artificial intelligence (AI) Urine Sediment Analysis at the ACVIM (American College of Veterinary Internal Medicine) Forum in Louisville, Kentucky, June 19-21, 2025. Zoetis has scheduled two poster sessions, where experts will share new data on how AI-powered detection of urine sediment elements compares to that of board-certified veterinary clinical pathologists.1,2
Vetscan Imagyst AI Urine Sediment uses deep-learning AI algorithms to provide a comprehensive in-clinic analysis of a patient’s fresh urine sediment, analyzing ~ 1000 microscopic fields. With consistent and accurate1,2 results within minutes,3 it equips veterinary professionals to guide informed and rapid treatment decisions to deliver individualized care.
Cory Penn DVM, Head of Global Diagnostics Portfolio Platform Support, Medical Affairs, Zoetis, said: “A complete urinalysis is a vital part of the diagnostic evaluation of veterinary patients. With Vetscan Imagyst AI Urine Sediment – and supported by our connected portfolio of advanced diagnostic tools – we have been able to streamline workflows, while simplifying and standardizing urine sediment processing and evaluation, for fast, accurate1,2 urine sediment results in the veterinary hospital.
“We are pleased to be sharing our latest data and scientific findings on the effectiveness and clinical importance of AI-powered urine sediment evaluation at ACVIM 2025, and showcasing how Zoetis continues to drive meaningful innovation in veterinary diagnostics for the benefit of patient outcomes and clinical teams.”
A urine sediment exam analyzes different elements in an animal’s urine, such as red and white blood cells, crystals, bacteria, and casts. It is essential for a complete urinalysis because it provides valuable insights into an animal’s health, helping to diagnose urinary tract problems, reveal hidden issues that could otherwise be missed, and guide treatment decisions.
The deep learning system that powers Vetscan Imagyst AI Urine Sediment uses a large number of small filters to extract an extensive set of features from an image, which are then applied to a convolutional deep neural network. Deep learning AI excels in identifying often difficult-to-visualize urine sediment elements.
The tool is part of Zoetis’ comprehensive diagnostics portfolio, offering access to expert clinical pathologist insights with Digital Cytology or Add-on Expert Review*. Veterinarians can also access an integrated global support network of board-certified specialists and pathologists through the Zoetis Virtual Laboratory.
The scientific abstracts will be presented by Zoetis at ACVIM 2025 on June 19, 5:30PM-7:30PM ET at the Kentucky International Convention Center. They include:
- Title: ‘Assessment of an Evolved Deep Learning Artificial Intelligence Algorithm for Canine/Feline Urine Sediment Samples’ by Mary Lewis, MS, DVM, Diplomate ACVP, Veterinary Clinical Pathologist; Anonda Haskin, DVM, Medical Platform Lead – Zoetis Global Diagnostics; Dan Lin, PhD; Eric Morissette, BSc, DVM, Diplomate ACVP – Zoetis Global Diagnostics; Kristin Owens, DVM, Diplomate ACVP, Clinical Pathologist – Zoetis Global Diagnostics, and Cory Penn, DVM, Head of Global Diagnostics Portfolio Platform Support, Medical Affairs – Zoetis Global Diagnostics.
- Title: ‘Deep Learning Algorithm for Evaluation of Less Common Crystals and Spermatozoa in Canine/Feline Urine Sediment’ by Mary Lewis, MS, DVM, Diplomate ACVP, Veterinary Clinical Pathologist; Anonda Haskin, DVM, Medical Platform Lead – Zoetis Global Diagnostics; Dan Lin, PhD; Eric Morissette, BSc, DVM, Diplomate ACVP – Zoetis Global Diagnostics; Kristin Owens, DVM, Diplomate ACVP, Clinical Pathologist – Zoetis Global Diagnostics, and Cory Penn, DVM, Head of Global Diagnostics Portfolio Platform Support, Medical Affairs – Zoetis Global Diagnostics.
Zoetis is a Bronze Sponsor of the event, which provides advanced and specialist-level education in veterinary internal medicine. Zoetis Global Chief Medical Officer, Richard Goldstein DVM, DACVIM, DECVIM-CA, will speak in a session on canine kidney disease (CKD) that looks at the latest insights into CKD progression. Dr Goldstein will analyze new clinical observations, prevalence data and histopathologic findings and set out how to apply these insights to improve patient monitoring, therapeutic strategies, and clinical outcomes.
The lecture, entitled ‘Progress of Canine CKD in 2025: What we are learning and where we are heading’, takes place on June 20 from 12:00PM-1.30PM ET at the Marriott Louisville, Marriot Ballroom Salons VII-X.
To view the full Zoetis diagnostics portfolio, visit https://www.zoetisdiagnostics.com/us
*Additional costs may apply.
References
- Data on file, Study No. DHX6Z-US-24-275
- Data on file, Study No. DHX6Z-US-24-276
- Data on file. Study No. DHXMZ-US-23-218
About Zoetis
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees.
DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects, expectations regarding products and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management’s underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.
# # #
All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. © 2025 Zoetis Services LLC. All rights reserved. VTS-01729
